Aridis Pharmaceuticals, Inc. financial data

Location
983 University Avenue, Bldg. B, Los Gatos, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 6, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 23.8 % -45.8%
Debt-to-equity -147 % +16%
Return On Assets -12.3 % +92.6%
Operating Margin -3.95 % +99.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.6M shares +114%
Common Stock, Shares, Outstanding 44.6M shares +152%
Common Stock, Value, Issued 5K USD +150%
Weighted Average Number of Shares Outstanding, Basic 37.4M shares +111%
Weighted Average Number of Shares Outstanding, Diluted 37.4M shares +111%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 22.4M USD +680%
Research and Development Expense 17.4M USD -34.4%
General and Administrative Expense 5.86M USD -21.9%
Operating Income (Loss) -883K USD +97.2%
Net Income (Loss) Attributable to Parent -1.14M USD +96.5%
Earnings Per Share, Basic 0 USD/shares +92.7%
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35K USD -98.1%
Accounts Receivable, after Allowance for Credit Loss, Current 417K USD
Assets, Current 4.11M USD -52.4%
Property, Plant and Equipment, Net 511K USD -47.5%
Operating Lease, Right-of-Use Asset 1.07M USD -30%
Other Assets, Noncurrent 327K USD -14.6%
Assets 6.53M USD -46.1%
Accounts Payable, Current 5.41M USD +27.9%
Employee-related Liabilities, Current 435K USD -28.1%
Accrued Liabilities, Current 7.69M USD -9.45%
Contract with Customer, Liability, Current 380K USD -98.1%
Liabilities, Current 17.5M USD -58.3%
Contract with Customer, Liability, Noncurrent 737K USD -13.7%
Operating Lease, Liability, Noncurrent 854K USD -40.3%
Liabilities 18.3M USD -59.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 7.79M USD
Retained Earnings (Accumulated Deficit) -190M USD -2.26%
Stockholders' Equity Attributable to Parent -11.8M USD +67.1%
Liabilities and Equity 6.53M USD -46.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4M USD +60.6%
Net Cash Provided by (Used in) Financing Activities 263K USD -94.1%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 44.6M shares +152%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.74M USD +34.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 535K USD -82.9%
Operating Lease, Liability 1.43M USD -26.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6.65M USD
Lessee, Operating Lease, Liability, to be Paid 1.53M USD -29%
Property, Plant and Equipment, Gross 2.76M USD -5.45%
Operating Lease, Liability, Current 576K USD +9.51%
Lessee, Operating Lease, Liability, to be Paid, Year Two 646K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 158K USD -74.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 97K USD -50%
Lessee, Operating Lease, Liability, to be Paid, Year Three 666K USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 60M shares 0%
Additional Paid in Capital 171M USD +11.3%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 5K USD -16.7%
Depreciation, Depletion and Amortization 87K USD -33.6%
Share-based Payment Arrangement, Expense 862K USD -52.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%